Chemours (NYSE:CC) Price Target Increased to $25.00 by Analysts at BMO Capital Markets

Chemours (NYSE:CC) had its price objective lifted by BMO Capital Markets from $23.00 to $25.00 in a research note issued to investors on Thursday, November 7th, Stock Target Advisor reports. They currently have an outperform rating on the specialty chemicals company’s stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of other equities analysts also recently commented on the company. Royal Bank of Canada downgraded Chemours from an outperform rating to a sector perform rating and decreased their target price for the company from $32.00 to $16.00 in a research note on Friday, August 9th. Susquehanna Bancshares upgraded Chemours from a neutral rating to a positive rating and decreased their target price for the company from $37.00 to $18.00 in a research note on Tuesday, August 20th. Citigroup boosted their price objective on Chemours from $14.00 to $21.00 and gave the stock a neutral rating in a research report on Wednesday, November 6th. TheStreet downgraded Chemours from a b- rating to a c+ rating in a research report on Friday, August 9th. Finally, SunTrust Banks boosted their price objective on Chemours to $20.00 and gave the stock a hold rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of Hold and an average target price of $27.14.

Chemours stock traded down $0.11 during midday trading on Thursday, hitting $18.43. The stock had a trading volume of 1,871,121 shares, compared to its average volume of 2,599,717. The company has a current ratio of 1.72, a quick ratio of 0.98 and a debt-to-equity ratio of 5.05. The stock has a market cap of $3.03 billion, a P/E ratio of 3.25, a P/E/G ratio of 0.49 and a beta of 2.57. Chemours has a 12 month low of $11.71 and a 12 month high of $41.60. The business has a fifty day moving average price of $16.02 and a 200 day moving average price of $19.22.

Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.03. Chemours had a return on equity of 58.38% and a net margin of 7.24%. The firm had revenue of $1.39 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the company earned $1.49 earnings per share. Chemours’s quarterly revenue was down 14.6% on a year-over-year basis. On average, equities analysts anticipate that Chemours will post 2.43 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 5.43%. The ex-dividend date is Thursday, November 14th. Chemours’s dividend payout ratio is currently 17.64%.

In related news, COO Mark Newman purchased 20,000 shares of the stock in a transaction dated Wednesday, September 11th. The shares were acquired at an average cost of $16.42 per share, for a total transaction of $328,400.00. Following the acquisition, the chief operating officer now directly owns 114,261 shares in the company, valued at approximately $1,876,165.62. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.34% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Investors Research Corp boosted its holdings in Chemours by 148.1% during the second quarter. Investors Research Corp now owns 1,206 shares of the specialty chemicals company’s stock valued at $29,000 after acquiring an additional 720 shares during the period. Point72 Hong Kong Ltd bought a new stake in Chemours during the second quarter valued at about $29,000. Parallel Advisors LLC boosted its holdings in Chemours by 479.4% during the third quarter. Parallel Advisors LLC now owns 2,312 shares of the specialty chemicals company’s stock valued at $35,000 after acquiring an additional 1,913 shares during the period. Quadrant Capital Group LLC raised its position in shares of Chemours by 423.4% during the third quarter. Quadrant Capital Group LLC now owns 2,727 shares of the specialty chemicals company’s stock valued at $36,000 after buying an additional 2,206 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its position in shares of Chemours by 41.7% during the third quarter. Oppenheimer Asset Management Inc. now owns 3,782 shares of the specialty chemicals company’s stock valued at $56,000 after buying an additional 1,113 shares during the last quarter. Hedge funds and other institutional investors own 79.60% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Article: What Are Treasury Bonds?

Analyst Recommendations for Chemours (NYSE:CC)

Leave a Reply

Your email address will not be published. Required fields are marked *

*